Do you routinely obtain CPS assay to assess candidacy for chemoimmunotherapy in newly diagnosed metastatic esophageal/GEJ/gastric adenocarcinoma?

I am still apt to assess tumor PD-L1 CPS to help inform long-term benefit from first-line chemoimmunotherapy in a patient with metastatic disease. Intrapatient, interlesional heterogeneity for PD-L1 CPS has also been recognized in the literature corresponding to discordance in levels of PD-L1 CPS po...

Even though FDA approval is not contingent on CPS score, it would still be a good idea to test for it. I test all patients at diagnosis of metastatic disease, and use assay 28-8 for nivolumab, as I intend to use nivolumab and chemotherapy as my preferred treatment approach.